Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Quest Diagnostics Inc's focus diagnostics receives FDA clearance for moderate complexity simplexa HSV 1 & 2 Direct molecular test for aiding the diagnosis of encephalitis


Monday, 24 Mar 2014 09:12am EDT 

Quest Diagnostics Inc:Says its focus diagnostics products business has received expedited FDA 510(k) clearance and CLIA moderate complexity categorization for its new Simplexa HSV 1 & 2 Direct molecular test on the 3M Integrated Cycler.Encephalitis is an inflammation of the brain often caused by the herpes simplex or other viruses. 

Company Quote

64.41
0.89 +1.40%
21 Nov 2014